Aravive (NASDAQ:ARAV) and Beyondspring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Volatility & Risk
Aravive has a beta of 3.52, suggesting that its share price is 252% more volatile than the S&P 500. Comparatively, Beyondspring has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
41.7% of Aravive shares are owned by institutional investors. Comparatively, 6.6% of Beyondspring shares are owned by institutional investors. 39.8% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Aravive and Beyondspring’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aravive||$4.75 million||19.84||-$18.22 million||($1.57)||-3.75|
Aravive has higher revenue and earnings than Beyondspring. Beyondspring is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for Aravive and Beyondspring, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aravive currently has a consensus target price of $28.75, suggesting a potential upside of 388.12%. Beyondspring has a consensus target price of $35.00, suggesting a potential upside of 217.32%. Given Aravive’s higher probable upside, analysts clearly believe Aravive is more favorable than Beyondspring.
This table compares Aravive and Beyondspring’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Aravive beats Beyondspring on 9 of the 10 factors compared between the two stocks.
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.